Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.

about

Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.

P2860

Q47555447-D580F144-C2F3-4192-8338-C7870FA8FF40

P2860

Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.

Item

http://www.wikidata.org/entity/Q41626170

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.

@en

type

Item

label

Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.

@en

prefLabel

Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.

@en

P1476

Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.

@en

P2093

Bhim Singhal

http://www.w3.org/2001/XMLSchema#string

Jui Dilip Jade

http://www.w3.org/2001/XMLSchema#string

Srishti Bansi

http://www.w3.org/2001/XMLSchema#string

P2860

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

The clinical course of neuromyelitis optica (Devic's syndrome).

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.

Neuromyelitis optica treatment: analysis of 36 patients.

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.

Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.

P304

229-232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/AIAN.AIAN_499_16

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28904454

http://www.w3.org/2001/XMLSchema#string

P932

5586117

http://www.w3.org/2001/XMLSchema#string

Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.

about

P2860

P2860

Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932